GNPX - Genprex, Inc. Common Stock

Day 1m 10m 60m PreMarket Market AfterHours Gap
0.7 -0.09 (-12.71%) 0.0 (-0.21%) -0.02 (-3.17%) -0.02 (-3.17%) -0.03 (-4.86%) -0.06 (-8.37%) -0.19 (-22.0%) -0.18 (-21.29%)

Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.

Category: PHARMACEUTICAL PREPARATIONS
Market Period: Market

Earnings & Ratios

Basic EPS:
-0.17
Diluted EPS:
Basic P/E:
-3.5941
Diluted P/E:
RSI(14) 1m:
29.78
VWAP:
0.6
RVol:
0.6397

Events

Period Kind Movement Occurred At
1m Price decrease 1m 0.67 -0.01 (-1.73%) Oct 16 09:29
1m Price decrease 1m 0.68 -0.01 (-1.46%) Oct 16 09:22
1m Price increase 1m 0.69 +0.01 (+1.53%) Oct 16 09:21
1m Price increase 1m 0.68 +0.01 (+1.03%) Oct 16 09:19
1m Price decrease 1m 0.68 -0.01 (-1.11%) Oct 16 09:17

Related News